Frazier Life Sciences Public Fund, L.P. 13D and 13G filings for Trevi Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 11:21 am Purchase |
2024-12-31 | 13G | Trevi Therapeutics, Inc. TRVI |
Frazier Life Sciences Public Fund, L.P. | 10,664,774 11.900% |
3,283,684 (+44.49%) |
Filing |
| 2024-11-06 10:30 am Purchase |
2024-09-30 | 13G | Trevi Therapeutics, Inc. TRVI |
Frazier Life Sciences Public Fund, L.P. | 7,381,090 10.200% |
717,500 (+10.77%) |
Filing |
| 2022-10-07 2:51 pm Purchase |
2022-10-05 | 13G | Trevi Therapeutics, Inc. TRVI |
Frazier Life Sciences Public Fund, L.P. | 6,663,590 11.400% |
2,847,131 (+74.60%) |
Filing |
| 2022-04-18 1:32 pm Purchase |
2022-04-11 | 13G | Trevi Therapeutics, Inc. TRVI |
Frazier Life Sciences Public Fund, L.P. | 3,816,459 10.000% |
3,816,459 (New Position) |
Filing |